Literature DB >> 7512319

Elevated expression of messenger RNA for peripheral myelin protein 22 in biopsied peripheral nerves of patients with Charcot-Marie-Tooth disease type 1A.

H Yoshikawa1, T Nishimura, Y Nakatsuji, H Fujimura, M Himoro, K Hayasaka, S Sakoda, T Yanagihara.   

Abstract

The human peripheral myelin protein 22 (PMP-22) gene has been mapped to chromosome 17p11.2 in the duplicated region associated with Charcot-Marie-Tooth disease type 1A. Southern blot analysis using PMP-22 as a probe indicated that the PMP-22 gene was duplicated in 5 patients from unrelated Japanese families with Charcot-Marie-Tooth disease type 1. In order to investigate whether or not an extra copy of PMP-22 has an effect on its gene expression, we analyzed relative expression of messenger RNA for PMP-22 and protein 0 (P0) against beta-actin by Northern blotting in biopsied nerves of the patients with type 1A disease, and compared the results with those of patients having other demyelinating neuropathies and the autopsied nerves of patients without neuropathies. The relative expression of PMP-22 messenger RNA in 5 patients with Charcot-Marie-Tooth disease type 1A was significantly higher than that in 5 patients with other demyelinating neuropathies (p < 0.05). There was no statistically significant difference in P0 expression between them. This study provided direct evidence for elevated expression of PMP-22 in peripheral nerves of patients with Charcot-Marie-Tooth disease type 1A as the result of a gene dosage effect. However, the relation between elevated expression of PMP-22 and the mechanism causing demyelination remains undetermined.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7512319     DOI: 10.1002/ana.410350412

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  19 in total

Review 1.  Myelin disorders: Causes and perspectives of Charcot-Marie-Tooth neuropathy.

Authors:  Gerd Meyer zu Hörste; Thomas Prukop; Klaus-Armin Nave; Michael W Sereda
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

Review 2.  Charcot-Marie-Tooth disease: lessons in genetic mechanisms.

Authors:  J R Lupski
Journal:  Mol Med       Date:  1998-01       Impact factor: 6.354

Review 3.  Neuropathology of Charcot-Marie-Tooth and related disorders.

Authors:  J Michael Schröder
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 4.  Molecular genetics of autosomal-dominant demyelinating Charcot-Marie-Tooth disease.

Authors:  Henry Houlden; Mary M Reilly
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 5.  Inherited focal, episodic neuropathies: hereditary neuropathy with liability to pressure palsies and hereditary neuralgic amyotrophy.

Authors:  Phillip F Chance
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

6.  Upregulation of the endosomal-lysosomal pathway in the trembler-J neuropathy.

Authors:  L Notterpek; E M Shooter; G J Snipes
Journal:  J Neurosci       Date:  1997-06-01       Impact factor: 6.167

7.  PMP22 expression in dermal nerve myelin from patients with CMT1A.

Authors:  Istvan Katona; Xingyao Wu; Shawna M E Feely; Stephanie Sottile; Carly E Siskind; Lindsey J Miller; Michael E Shy; Jun Li
Journal:  Brain       Date:  2009-05-15       Impact factor: 13.501

8.  Copy number variation upstream of PMP22 in Charcot-Marie-Tooth disease.

Authors:  Marian A J Weterman; Fred van Ruissen; Marit de Wissel; Lou Bordewijk; Johnny P A Samijn; W Ludo van der Pol; Farid Meggouh; Frank Baas
Journal:  Eur J Hum Genet       Date:  2009-11-04       Impact factor: 4.246

Review 9.  Molecular anatomy and genetics of myelin proteins in the peripheral nervous system.

Authors:  G J Snipes; U Suter
Journal:  J Anat       Date:  1995-06       Impact factor: 2.610

Review 10.  Dysregulation of ErbB Receptor Trafficking and Signaling in Demyelinating Charcot-Marie-Tooth Disease.

Authors:  Samuel M Lee; Lih-Shen Chin; Lian Li
Journal:  Mol Neurobiol       Date:  2016-01-05       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.